Treatment of HIV-1 infection: An overview of new strategies and novel agents

Infections in Medicine

Volumn 13, Issue 10, 1996, Pages 903-911

  Kilby, J Michael ^a,b   Saag, Michael S ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Acquired immune deficiency syndrome (AIDS); Human immunodeficiency virus (HIV); Indinavir; Lamivudine (3TC); Nonnucleoside reverse transcriptase inhibitors; Ritonavir; Saquinavir; Stavudine (d4T)

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 3 [(4,7 DIMETHYL 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; 9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ANTIRETROVIRUS AGENT; ATEVIRDINE; CASTANOSPERMINE; CD4 ANTIGEN; CYCLOSPORIN A; DELAVIRDINE; DIDANOSINE; EMIVIRINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOVIRIDE; NEVIRAPINE; NUCLEOSIDE ANALOG; PENTOXIFYLLINE; PREDNISONE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRECOVIRSEN; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PERIPHERAL NEUROPATHY; RASH; TASTE DISORDER;

EID: 0030412180     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Liu R, Paxton WA, Choe S, et al: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiple-exposed individuals to HIV-1 infection. Cell 86:367-377, 1996.
2. Feng Y, Broder CC, Dennedy PE, et al: HIV-1 entry cofactor: Functional cDNA cloning of a seven transmembrane G protein-coupled receptor. Science 272:872-877, 1996.
3. Saag MS, Holodniy M, Kuritzkes DR, et al: HIV viral load markers in clinical practice. Nature Medicine 2:625-629, 1996.
4. Fischl MA, Richman DD, Grieco MH, et al: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317:185-191, 1987.
5. Fischl MA, Richman DD, Hansen N, et al: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 112:727-737, 1990.
6. Volberding PA, Lagakos SW, Koch MA, et al: Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 322:941-949, 1990.
7. Hamilton JD, Hartigan PH, Simberkoff MS, et al: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 326:437-443, 1992.
8. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343:871-881, 1994.
9. Hirsch MS, D'Aquila RT: Therapy for human immunodeficiency virus infection. N Engl J Med 328:1686-1695, 1993.
10. Saag MS: Nucleoside analogs: Adverse effects. Hosp Prac 27(suppl):26-36, 1992.
11. Cooley TP, Kunches LM, Saunders CA, et al: Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a phase I trial. N Engl J Med 322:1340-1345, 1990.
12. Lambert JS, Seidlin M, Reichman RC, et al: 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: Results of a phase I trial. N Engl J Med 322:1333-1340, 1990.
13. Kahn JO, Lagakos SW, Richman DD, et al: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 327:581-587, 1992.
14. 3. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995. (Abstract LB-1)
15. Fischl MA, Olson RM, Follansbee SE, et al: Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 118:762-769, 1993.
16. Abrams DI, Goldman AI, Launer C, et al: A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 330:657-662, 1994.
17. Collier AC, Coombs RW, Fischl MA, et al: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 119:786-793, 1993.
18. Meng T-C, Fischl MA, Boota AM, et al: Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Intern Med 116:13-20, 1992.
19. Skowron G, Bozzette SA, Lim L, et al: Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 118:321-330, 1993.
20. The European Delta Trial. 5th European Conference on Clinical Aspects and Treatment of AIDS, 1995. Abstract.
21. 3. Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996. Abstract.
22. Adler MH, Anderson RE, Rutkiewicz V, et al: Clinical course of long-term therapy with stavudine (D4T). 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., 1994. (Abstract M14)
23. Pavia AT, Gathe J, BMS-019 Study Group Investigators, et al: Clinical efficacy of stavudine compared to zidovudine in ZDV-pretreated HIV positive patients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995. (Abstract I169)
24. Pollard R, Peterson D, Hardy D, et al: Antiviral effect and safety of stavudine and didanosine combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blinded trial. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996. (Abstract 197)
25. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699, 1995.
26. Wainberg MA, Drosopoulos WC, Salomon H, et al: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285, 1996.
27. 3. 2nd National Conference on Human Retroviruses, Washington, DC, 1995. (Abstract LB31)
28. Eron J, Benoit S, Jemsek J, et al: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 333:1662, 1996.
29. 3. 2nd National Conference on Human Retroviruses, Washington, DC, 1995. (Abstract LB32)
30. 3. 2nd National Conference on Human Retroviruses, Washington, DC, 1995. (Abstract LB35)
31. Richman DD: Resistance of clinical isolates of HIV to antiretroviral agents. Antimicrob Agents Chemother 37:1207-1213, 1993.
32. Roberts NA, Martin JA, Kinchington D, et al: Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361, 1990.
33. Erickson J, Neidhart DJ, VanDrie J, et al: Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249:527-533, 1990.
34. Johnson VA, Merrill DP, Chou T-C, et al: HIV-1 inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon alphaA against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 166:1143-1146, 1992.
35. Fischl M, Richman D, Flexner C, et al: Phase I study of 2 formulations and dose schedules of SC-52151, a protease inhibitor. 2nd National Conference on Human Retroviruses and Related Infections, Washington, DC, 1995. (Abstract 186)
36. Vella S: HIV therapy advances. Update on a proteinase inhibitor. AIDS 8(suppl 3):S25, 1994.
37. Collier AC, Coombs RW, Schoenfeld DA, et al: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 334:1011, 1996.
38. Schapiro JM, Winters MA, Merigan TC: First efficacy and safety results of the high dose saquinavir monotherapy trials. 2nd National Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1995. (Abstract LB2)
39. Kaplan AH, Michael SF, Wehbie RS, et al: Selection of multiple HIV-1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A 91:5597-5601, 1994.
40. Deutsch P, Teppler H, Squires K, et al: Antiviral activity of L-735,524, an HIV protease inhibitor, in infected patients. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., 1994. (Abstract I59)
41. Condra JH, Schleif WA, Blahy OM, et al: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569, 1995.
42. Markowitz M, Saag MS, Powderly WG, et al: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 333:1534, 1995.
43. Cameron B, Heath-Chiozzi M, Kravcik S, et al: Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
44. Mathez D, De Truchis P, Gorin I, et al: Ritonavir, AZT, DDC, as a triple combination in AIDS patients. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996. (Abstract 285)
45. Steigbigel RT, Berry P, Mellors J, et al: Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) at escalating dose. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996. (Abstract 146)
46. Condra JH, Schleif WA, Blahy OM, et al: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571, 1995.
47. Gulick R, Mellors J, Havlir D, et al: Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine (3TC). 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996. (Abstract LB7)
48. Miyasaka T, Tanaka H, Baba M, et al: A novel lead for specific anti-HIV-1 agents. J Med Chem 32:2507, 1989.
49. Pauwels R, Andries K, Desmyter J, et al: Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474, 1990.
50. Pauwels R, Andries K, Debyser Z, et al: Potent and highly selective HIV-1 inhibition by a series of alpha-anilophenylacetamide derivatives targeted at HIV-1 RT. Proc Natl Acad Sci U S A 90:1711-1715, 1993.
51. Merluzzi VJ, Hargrave KD, Labadia M, et al: Inhibition of HIV-1 replication by a non-nucleoside RT inhibitor. Science 250:1411-1413, 1990.
52. Goldman ME, Nunberg JH, O'Brien JA, et al: Pyridinone derivatives: Specific HIV-1 RT inhibitors with antiviral activity. Proc Natl Acad Sci USA 88:6863-7, 1991.
53. Romero DL, Busso M, Tan C-K, et al: Nonnucleoside RT inhibitors that potently and specifically block HIV-1 replication. Proc Natl Acad Sci U S A 88:8806-8810, 1991.
54. Young SD, Britcher SF, Tran LO, et al: L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the HIV-1 reverse transcriptase. Antimicrob Agents Chemother 39:2602-2605, 1995.
55. Saag MS, Emini EA, Laskin OL, et al: A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 329:1065-1072, 1993.
56. -et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122, 1995.
57. Myers MW, Montaner JG, and the Incas Study Group: A randomized, double-blinded comparative trial of the effects of zidovudine, didanosine, and nevirapine combinations in antiviral naive, AIDS-free, HIV-infected patients with CD4 counts 200-600/mm3. XIth International Conference on AIDS, Vancouver, 1996. Abstract
58. Kilby JM, Saag MS: Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infectious Agents and Disease 3:313-323, 1994.
59. Lori F, Malykh A, Cara A, et al: Hydroxyurea as an inhibitor of HIV-1 replication. Science 266:801-805, 1994.
60. Bagasra O, Whittle P, Heins B, et al: Anti-HIV-1 activity of sulfated monosaccharides: Comparison with sulfated polysaccharides and other polyions. J Infect Dis 164:1082-1090, 1991.
61. Schooley RT, Merigan TC, Gaut P, et al: Recombinant soluble CD4 therapy in patients with AIDS and AIDS-related complex. Ann Intern Med 112:247-253, 1990.
62. De Clercq E, Yamamoto, Pauwels R, et al: Highly potent and selective inhibition of HIV by the bicyclam derivative JM3100. Antimicrob Agents Chemother 38:668-674, 1994.
63. Steinklasserer A, Harrison R, Billich A, et al: Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against HIV-1. J Virol 69:814-824, 1995.
64. Dyda F, Hickman AB, Jenkins TM, et al: Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases. Science 266:1981-1986, 1994.
65. Hsu M-C, Schutt AD, Holly M, et al: Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 254:1799-1801, 1991.
66. Ratner L: Glucosidase inhibitors for treatment of HIV-1 infection. AIDS Research and Human Retrovir 8:165-173, 1992.
67. Rice WG, Schaeffer CA, Harten B, et al: Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 361:473-475, 1993.
68. Buchschacher GL: Molecular targets of gene transfer therapy for HIV infection. JAMA 269:2880-2886, 1993.
69. Lisziewicz J, Sun D, Hotman M, et al: Specific inhibition of HIV-1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc Natl Acad Sci U S A 89:11209-11213, 1992.
70. Antisense has growing pains. Science 270:575-576.
71. Malim MH, Freimuth WW, Liu J, et al: Stable expression of transdominant Rev protein in human T cells inhibits HIV replication. J Exp Med 176:1197-1201, 1992.
72. Yu M, Ojwang J, Yamada O, et al: A hairpin ribozyme inhibits expression of diverse strains of HIV-1. Proc Natl Acad Sci U S A 90:6340-6344, 1993.
73. Redfield RR, Birx DL, Ketter N, et al: A phase 1 evaluation of the immunogenicity of vaccination with recombinant pg160 in patients with early HIV infection. N Engl J Med 324:1677-1684, 1991.
74. Mosmann TR: Cytokine patterns during the progression to AIDS. Science 265:193-194, 1994.
75. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, et al: Thalidomide inhibits the replication of HIV-1. Proc Natl Acad Sci U S A 90:5974-5978, 1993.
76. Dezube BJ: Pentoxifylline for the treatment of infection with HIV. Clin Infect Dis 18:285-287, 1994.
77. Clerici M, Lucey DR, Berzofsky JA, et al: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262: 1721-1724, 1993.
78. Kovacs JA, Baseler M, Dewar RJ, et al: Increases in CD4 lymphocytes with intermittent courses of interleukin-2 in patients with HIV infection. N Engl J Med 332:567-575, 1995.
79. O'Brien WA, Grovit-Ferbas K, Namazi A, et al: HIV-1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86:1082-1089, 1995.
80. Andrieu J-M, Lu W, Levy R: Sustained increases in CD4 cell counts in asymptomatic HIV-1 seropositive patients treated with prednisolone for 1 year. J Infect Dis 171:523-530, 1995.
81. Braun JF, Powderly WG, Steinberg CL, et al: A guide to underground AIDS therapies. Patient Care August 1993, pp 53-70.